BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

s Keytruda. BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

去年11月，BioNTech和普米斯生物联合开发了一款名为BNT327的“双特异性抗体”药物。BioNTech后来预付了5500万美元，并承诺支付高达10亿美元的里程碑付款，以确保大中华区以外的权益。

And, in non-small cell lung cancer with specific EGFR mutations, MI Cancer Seek can be used with approved tyrosine kinase ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

It said it saw BNT327’s dual-target approach as a significant advancement over single-action therapies like Merck’s Keytruda ...